13 results
To study whether dipyridamole reduces gastrointestinal absorption of metformin.
Primary objective: The primary objective of the study is to determine the effect of oral dipyridamole treatment on the innate immune response induced by a lipopolysaccharide (LPS) challenge. Various pro- and anti-inflammatory cytokines will be…
1. Creating a reproducible and valid method for adenosine measurement2. Studying the effect of dipyridamole on the endogenous adenosine concentration before and after CPT.
Explore 4 week post-treatment effect of seven day administration of dipyridamole on nucleoside transport inhibition.
To study the effect of oral pretreatment with dipyridamole on troponin-I release after CABG. Secondary objectives are whether oral pretreatment with dipyridamole reduces postoperative CABG arrhythmias, prolonged inotropic support, and duration of…
The purpose of this project is to explore the interaction between caffeine and dipyridamole on ischemia-reperfusion injury in the forearm.
Creating a reproducible and valid method for adenosine measurement
The purpose of this project is to explore whether a short treatment with dipyridamole (2.5 days; i.e. 5 capsules) can reduce ischemia-reperfusion injury in the forearm.
To test the hypothesis that dipyridamole improves tolerance to ischemia-reperfusion in patients undergoing elective PCI.
Primary objective: To assess the efficacy of T-DXd relative to platinum with pemetrexed plus pembrolizumab by assessment of PFS by BICR in participants with unresectable, locally advanced, or metastatic NSCLC harboring HER2 exon 19 or 20 mutations.
To evaluate the efficacy of lebrikizumab compared with placebo in patients not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16
Primary Objective: to obtain reliable estimates of the rates of vascular death and non-fatal stroke in patients with atrial fibrillation and a recent anticoagulation-associated ICH who are treated with apixaban versus those who are treated with APDs…
- To assess the safety and tolerability and to determine the RP2D of T-DXd plus durvalumab in combination with cisplatin, carboplatin or pemetrexed